Organovo Holdings Inc
NASDAQ:VIVS

Watchlist Manager
Organovo Holdings Inc Logo
Organovo Holdings Inc
NASDAQ:VIVS
Watchlist
Price: 2.32 USD 1.31%
Market Cap: 6.1m USD

ROE
Return on Equity

-378.4%
Current
-116%
Average
-23%
Industry

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-378.4%
=
Net Income
-12.4m
/
Equity
2m

ROE Across Competitors

No Stocks Found

Organovo Holdings Inc
Glance View

Market Cap
6.1m USD
Industry
Biotechnology

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

VIVS Intrinsic Value
1.13 USD
Overvaluation 51%
Intrinsic Value
Price
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-378.4%
=
Net Income
-12.4m
/
Equity
2m
What is the ROE of Organovo Holdings Inc?

Based on Organovo Holdings Inc's most recent financial statements, the company has ROE of -378.4%.

Back to Top